A Phase IIIB, Multicenter, Randomized, Parallel-Group, Open-Label Study to Evaluate the Effects of Ocrelizumab on Immune Responses in Patients With Relapsing Forms of Multiple Sclerosis

Trial Profile

A Phase IIIB, Multicenter, Randomized, Parallel-Group, Open-Label Study to Evaluate the Effects of Ocrelizumab on Immune Responses in Patients With Relapsing Forms of Multiple Sclerosis

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Sep 2017

At a glance

  • Drugs Ocrelizumab (Primary) ; Influenza virus vaccine
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 03 Oct 2016 Status changed from recruiting to active, no longer recruiting.
    • 01 Jun 2016 Planned End Date changed from 1 Oct 2022 to 1 Dec 2022.
    • 01 Jun 2016 Planned primary completion date changed from 1 Oct 2022 to 1 Dec 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top